Btai analyst report
WebAnalyst Ratings for Bioxcel Therapeutics Inc (BTAI) provide recommendations made by outside industry experts. Your browser of choice has not been tested for use with … WebApr 12, 2024 · Based on 4 Analyst Ratings Consensus Analyst Price Target $14.40 59.47% Upside Get indie Semiconductor Upgrade and Downgrade Alerts Sign-up to receive the latest news and ratings for INDI and its competitors with MarketBeat's FREE daily newsletter. INDI Analyst Ratings By Month INDI Price Targets by Month indie …
Btai analyst report
Did you know?
WebApr 6, 2024 · Analyst Forecast According to 16 analysts, the average rating for BTAI stock is "Buy." The 12-month stock price forecast is $57.03, which is an increase of 212.49% … WebApr 10, 2024 · BTAI Stock Overview. About the company. BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence …
WebApr 11, 2024 · A number of equities analysts recently weighed in on BTAI shares. Mizuho lifted their price target on BioXcel Therapeutics from $24.00 to $38.00 and gave the stock a “buy” rating in a research ... WebApr 6, 2024 · Bank of America has increased its price target on BioXcel Therapeutics ( NASDAQ: BTAI) after the New Haven, Connecticut-based biotech won the U.S. …
WebMar 18, 2024 · BioXcel Therapeutics, Inc. (NASDAQ:BTAI) is currently awaiting word from the FDA regarding the potential approval of BXCL501 for the treatment of agitation associated with schizophrenia and... WebBTAI Stock 12 Months Forecast. Average Price Target. $46.00. (146.52% Upside) Based on 7 Wall Street analysts offering 12 month price targets for Bioxcel Therapeuticsin the …
WebDec 6, 2024 · NTER equips homeland security partners with tools and resources to identify, report, and mitigate threats of terrorism and targeted violence to keep the Homeland safe primarily through two lines of effort: the Nationwide Suspicious Activity Reporting Initiative and Behavioral Threat Assessment Integration. spinnerets pronounceWebApr 10, 2024 · BTAI has been the topic of a number of research analyst reports. HC Wainwright cut their target price on BioXcel Therapeutics from $79.00 to $66.00 and set a “buy” rating on the stock in a ... spinneret mary jane watson marvelWebApr 10, 2024 · BioXcel Therapeutics ( NASDAQ:BTAI - Get Rating) last posted its quarterly earnings results on Thursday, March 9th. The company reported ($1.95) EPS for the quarter, missing the consensus estimate of ($1.49) by ($0.46). The firm had revenue of $0.24 million during the quarter, compared to analyst estimates of $1.08 million. spinnericycleWeb1 day ago · In a report released today, Corinne Jenkins from Goldman Sachs maintained a Hold rating on Bioxcel Therapeutics ( BTAI – Research Report ). The company’s shares closed yesterday at $16.69.... spinnergy solutions llcWebPrice To Free Cash Flow is a widely used stock evaluation measure. Find the latest Price To Free Cash Flow for BioXcel Therapeutics (BTAI) spinnerets pronunciationWebThe analyst firm set a price target for 66.00 expecting BTAI to rise to within 12 months (a possible 282.17% upside). 16 analyst firms have reported ratings in the last year. spinnerinoshibe twitterWebApr 12, 2024 · The latest price target for BioXcel Therapeutics ( NASDAQ: BTAI) was reported by Jefferies on March 10, 2024. The analyst firm set a price target for $22.00 expecting BTAI to rise to within... spinnerin canada tweed yarn